CoChat
Sign Up
Cited by 118

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Emergence and significance of carbohydrate-specific antibodies

Kappler, Katharina, Hennet, Thierry·2020·Genes & Immunity
DOI 10.1038/s41435-020-0105-9PMC PMC7449879
Open this paper in CoChat — free account

Abstract

Carbohydrate-specific antibodies are widespread among all classes of immunoglobulins. Despite their broad occurrence, little is known about their formation and biological significance. Carbohydrate-specific antibodies are often classified as natural antibodies under the assumption that they arise without prior exposure to exogenous antigens. On the other hand, various carbohydrate-specific antibodies, including antibodies to ABO blood group antigens, emerge after the contact of immune cells with the intestinal microbiota, which expresses a vast diversity of carbohydrate antigens. Here we explore the development of carbohydrate-specific antibodies in humans, addressing the definition of natural antibodies and the production of carbohydrate-specific antibodies upon antigen stimulation. We focus on the significance of the intestinal microbiota in shaping carbohydrate-specific antibodies not just in the gut, but also in the blood circulation. The structural similarity between bacterial carbohydrate antigens and surface glycoconjugates of protists, fungi and animals leads to the production of carbohydrate-specific antibodies protective against a broad range of pathogens. Mimicry between bacterial and human glycoconjugates, however, can also lead to the generation of carbohydrate-specific antibodies that cross-react with human antigens, thereby contributing to the development of autoimmune disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41435-020-0105-9

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Commonly recognized glycan epitopes by human antibodies. a N-acetyl-neuraminic acid (NeuAc) and N-glycolyl-neuraminic acid (NeuGc) differ only by the occurrence of an additional hydroxyl group in NeuGc. b Schematic structure of Forssman and Galili antigen. Glycosidic linkages are marked using the minimal nomenclature; α3 for α1–3, β3 for β1–3 and β4 for β1–4. c Schematic structure of ABO blood group antigens. d Chemical composition of galactose (Gal) and N-acetylgalactosamine (GalNAc) with highlighted acetamido group at C2. e Schematic structure of Lewis antigens Lewis A, B, X, and Y. f Structure of the P blood group antigens Pk, P, and P1.
Fig. 1 Commonly recognized glycan epitopes by human antibodies. a N-acetyl-neuraminic acid (NeuAc) and N-glycolyl-neuraminic acid (NeuGc) differ only by the occurrence of an additional hydroxyl group in NeuGc. b Schematic structure of Forssman and Galili antigen. Glycosidic linkages are marked using the minimal nomenclature; α3 for α1–3, β3 for β1–3 and β4 for β1–4. c Schematic structure of ABO blood group antigens. d Chemical composition of galactose (Gal) and N-acetylgalactosamine (GalNAc) with highlighted acetamido group at C2. e Schematic structure of Lewis antigens Lewis A, B, X, and Y. f Structure of the P blood group antigens Pk, P, and P1.CC BY · PubMed Central
Fig. 2 Antigen processing and presentation for different types of carbohydrate structures. Extracellular glycoproteins are engulfed in endocytic or phagocytic vesicles, broken down in phagolysosomes and fragments of the glycopeptide are loaded on major histocompatibility complex II (MHC-II) to be presented at the cell surface. A similar mechanism is applied for zwitterionic polysaccharides, however, with a different processing mechanism depending on nitric oxide (NO). Glycolipids are presented on CD1-type proteins that are similar to MHC-I after being captured by lipid transfer proteins, such as saposins. The mechanisms underlying the processing and presentation of soluble oligo- and polysaccharides are unknown but are likely to involve binding through C-type lectins expressed at the surface of antigen-presenting cells.
Fig. 2 Antigen processing and presentation for different types of carbohydrate structures. Extracellular glycoproteins are engulfed in endocytic or phagocytic vesicles, broken down in phagolysosomes and fragments of the glycopeptide are loaded on major histocompatibility complex II (MHC-II) to be presented at the cell surface. A similar mechanism is applied for zwitterionic polysaccharides, however, with a different processing mechanism depending on nitric oxide (NO). Glycolipids are presented on CD1-type proteins that are similar to MHC-I after being captured by lipid transfer proteins, such as saposins. The mechanisms underlying the processing and presentation of soluble oligo- and polysaccharides are unknown but are likely to involve binding through C-type lectins expressed at the surface of antigen-presenting cells.CC BY · PubMed Central
Fig. 3 T-cell-dependent and -independent activation of B-cells. T cells activate B-cells and promote antibody class switching through multiple interactions involving antigen-bound MHC-II with the T-cell receptor (TCR), and activation though the co-receptor systems CD40-CD40L, ICOS-ICOSL, PD1/PD1L, and CD28-CD80/86. In the absence MHC-II presentation of antigens to T cells, B-cell activation and immunoglobulin class-switching can be mediated through binding to the activating proteins BAFF and APRIL secreted by myeloid cells, such as dendritic cells (Dc). APRIL binds to its receptor TAC1 on B cells after docking to heparan sulfate proteoglycans (HSPG).
Fig. 3 T-cell-dependent and -independent activation of B-cells. T cells activate B-cells and promote antibody class switching through multiple interactions involving antigen-bound MHC-II with the T-cell receptor (TCR), and activation though the co-receptor systems CD40-CD40L, ICOS-ICOSL, PD1/PD1L, and CD28-CD80/86. In the absence MHC-II presentation of antigens to T cells, B-cell activation and immunoglobulin class-switching can be mediated through binding to the activating proteins BAFF and APRIL secreted by myeloid cells, such as dendritic cells (Dc). APRIL binds to its receptor TAC1 on B cells after docking to heparan sulfate proteoglycans (HSPG).CC BY · PubMed Central
Fig. 4 Molecular mimicry between animal glycan epitopes and bacterial glycans. a Schematic structure of the Galili xenoantigen and Escherichia coli O86 O-antigen expressed on lipopolysaccharide (LPS). The conserved Gal(α1–3)Gal motif is highlighted in blue. b Structures of lipooligosaccharides (LOS) of Neisseria meningitidis and Haemophilus ducreyi including the lacto-N-neotetraose (LNnT) epitope found in human milk oligosaccharides and on glycosphingolipids. c Similarity between the Lewis Y epitope and the LPS of Helicobacter pylori M019. d Schematic structure of the ganglioside GM1 and the LOS epitope of Campylobacter jejuni.
Fig. 4 Molecular mimicry between animal glycan epitopes and bacterial glycans. a Schematic structure of the Galili xenoantigen and Escherichia coli O86 O-antigen expressed on lipopolysaccharide (LPS). The conserved Gal(α1–3)Gal motif is highlighted in blue. b Structures of lipooligosaccharides (LOS) of Neisseria meningitidis and Haemophilus ducreyi including the lacto-N-neotetraose (LNnT) epitope found in human milk oligosaccharides and on glycosphingolipids. c Similarity between the Lewis Y epitope and the LPS of Helicobacter pylori M019. d Schematic structure of the ganglioside GM1 and the LOS epitope of Campylobacter jejuni.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 218

  1. Sterner E, Flanagan N, Gildersleeve JC. Perspectives on anti-glycan antibodies gleaned from development of a community resource database. ACS Chem Biol. 2016;11:1773–83. · DOI
  2. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012;13:448–62. · DOI
  3. Holden HM, Cook PaulD, Thoden JB. Biosynthetic enzymes of unusual microbial sugars. Curr Opin Struct Biol. 2010;20:543–50. · DOI
  4. Herget S, Toukach PV, Ranzinger R, Hull WE, Knirel YA, von der Lieth C. Statistical analysis of the Bacterial Carbohydrate Structure Data Base (BCSDB): characteristics and diversity of bacterial carbohydrates in comparison with mammalian glycans. BMC Struct Biol. 2008;8:35. · DOI
  5. Freeze HH, Hart GW, Schnaar RL Glycosylation Precursors. In: Varki ACR, Esko JD, et al., editor Essentials of glycobiology. 3rd ed., vol. Chapter 5. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2017.
  6. Varki A. Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution. Yearb Phys Anthropol.2001;33(Suppl):54–69. · DOI
  7. Chiani P, Bromuro C, Cassone A, Torosantucci A. Anti-beta-glucan antibodies in ealthy human subjects. Vaccine. 2009;27:513–9. · DOI
  8. Tytgat HL, Lebeer S. The sweet tooth of bacteria: common themes in bacterial glycoconjugates. Microbiol Mol Biol Rev. 2014;78:372–417. · DOI
  9. Bovin N, Obukhova P, Shilova N, Rapoport E, Popova I, Navakouski M, et al. Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies? Biochim Biophys Acta. 2012;1820:1373–82. · DOI
  10. Dotan N, Altstock RT, Schwarz M, Dukler A. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus. 2006;15:442–50. · DOI
  11. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, et al. Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol. 2009;46:3037–49. · DOI
  12. McMorrow IM, Comrack CA, Sachs DH, DerSimonian H. Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(a1,3)Galactose epitope. Transplantation. 1997;64:501–10. · DOI
  13. Lacroix-Desmazes S, Monthon L, Coutinho A, Kazatchkine MD. Analysis of the natural human IgG antibody repertoire: life-long stability of reactivities towards self antigens contrasts with age-dependent diversification of reactivities against bacterial antigens. Eur J Immunol. 1995;25:2598–604. · DOI
  14. Oyelaran O, McShane LM, Dodd L, Gildersleeve JC. Profiling human serum antibodies with a carbohydrate antigen microarray. J Proteome Res. 2009;8:4301–10. · DOI
  15. Mistou MY, Sutcliffe IC, van Sorge NM. Bacterial glycobiology: rhamnose-containing cell wall polysaccharides in Gram-positive bacteria. FEMS Microbiol Rev. 2016;40:464–79. · DOI · Paper page
  16. Giraud M, Naismith JH. The rhamnose pathway. Curr Opin Struct Biol. 2000;10:687–96. · DOI
  17. Muchmore EA, Diaz S, Varki A. A structural difference between the cell surfaces of humans and the great apes. Am J Phys Anthropol. 1998;107:187–98. · DOI · Paper page
  18. Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation. 2002;9:376–81. · DOI
  19. Padler-Karavani V, Varki A. Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation. 2011;18:1–5. · DOI · Paper page
  20. Galili U. Natural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics? Glycobiology. 2016;26:1140–50.
  21. Padler-Karavani V, Tremoulet AH, Yu H, Chen X, Burns JC, Varki A. A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease. PLoS ONE. 2013;8:e58443. · DOI
  22. Galili U, Macher BA, Buehler J, Shohet SB. Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1->3)-linked galactose residues. J Exp Med. 1985;162:573–82. · DOI
  23. Galili U. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med. 1984;160:1519–31. · DOI · Paper page
  24. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. One percent of human circulating B lymphocytes are capable of producing the natural anti-gal antibody. Blood. 1993;82:2485–93. · DOI
  25. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, McLeod Griffiss J. Interaction between human natural anti-a-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 1988;56:1730–7. · DOI
  26. Galili U, Swanson K. Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA. 1991;88:7401–4. · DOI
  27. Cooper DKC, Good AH, Koren E, Oriol R, Malcolm AJ, Ippolito RM, et al. Identification of a-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol. 1993;1:198–205. · DOI
  28. Joziasse DH, Oriol R. Xenotransplantation: the importance of the Gala1-3Gal epitope in hyperacute vascular rejection. Biochim Biophys Acta. 1999;1455:403–18. · DOI
  29. Hamanova M, Chmelikova M, Nentwich I, Thon V, Lokaj J. Anti-Gal IgM, IgA and IgG natural antibodies in childhood. Immunol Lett. 2015;164:40–3. · DOI
  30. Hakomori S. Glycolipids of tumor cell membrane. Adv Cancer Res. 1973;18:265–315. · DOI
  31. Bovin N, Obukhova P, Shilova N, Rapoport E, Popova I, Navakouski M, et al. Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies? Biochim Biophys Acta. 2012;1820:1373–82. · DOI
  32. Bello-Gil D, Khasbiullina N, Shilova N, Bovin N, Manez R. Repertoire of BALB/c mice natural anti-carbohydrate antibodies: mice vs. humans difference, and otherness of individual animals. Front Immunol. 2017;8:1449. · DOI
  33. Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;17:6272.
  34. Soejima M, Koda Y. Molecular mechanisms of Lewis antigen expression. Leg Med. 2005;7:266–9. · DOI
  35. Henry S, Oriol R, Samuelsson B. Lewis histo-blood group system and associated secretory phenotypes. Vox Sanguinis. 1995;69:166–82. · DOI
  36. Spitalnik PF, Spitalnik SL. The P blood group system: biochemical, serological, and clinical aspects. Transfus Med Rev. 1995;9:110–22. · DOI
  37. Steffensen R, Carlier K, Wiels J, Levery SB, Stroud M, Cedergren B, et al. Cloning and expression of the histo-blood group Pk UDP-galactose: Galb1–4Glcb1-Cera1,4-galactosyltransferase. J Biol Chem. 2000;275:16723–9. · DOI
  38. Thuresson B, Westman JS, Olsson ML. Identification of a novel A4GALT exon reveals the genetic basis of the P1/P2 histo-blood groups. Blood. 2011;117:678–87. · DOI
  39. Hellberg A, Poole J, Olsson ML. Molecular basis of the globoside-deficient Pk blood group phenotype. J Biol Chem. 2002;277:29455–9. · DOI
  40. Holodick NE, Rodriguez-Zhurbenko N, Hernandez AM. Defining natural antibodies. Front Immunol. 2017;8:872. · DOI
  41. Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Semin Immunopathol. 2005;26:347–62. · DOI
  42. Houghteling PD, Walker WA. Why is initial bacterial colonization of the intestine important to infants’ and children’s health? J Pediatr Gastroenterol Nutr. 2015;60:294–307. · DOI
  43. Macher BA, Galili U. The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta. 2008;1780:75–88. · DOI · Paper page
  44. Zhou Z, Zhang Y, Hu Y, Wahl LM, Cisar JO, Notkins AL. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe. 2007;1:51–61. · DOI
  45. Puga I, Cerutti A. Protection by natural IgG: a sweet partnership with soluble lectins does the trick! The. EMBO J. 2013;32:2897–9. · DOI
  46. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7:812–8. · DOI
  47. Ikematsu H, Schettino E, Casali P. Structure of the VH-D-JH segments of human natural polyreactive IgM and IgG antibodies. Use of germline or somatically mutated forms of commonly expressed VH genes. Ann N Y Acad Sci. 1995;764:362–9. · DOI
  48. Mouthon L, Haury M, Lacroix-Desmazes S, Barreau C, Coutinho A, Kazatchkine MD. Analysis of the normal human IgG antibody repertoire. Evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissue. J Immunol. 1995;154:5769–78. · DOI · Paper page
  49. Ochsenbein AF, Zinkernagel RM. Natural antibodies and complement link innate and acquired immunity. Immunol Today. 2000;21:624–30. · DOI
  50. Toellner K, Jenkinson WE, Taylor DR, Khan M, Sze DM, Sansom DM, et al. Low-level hypermutation in T cell–independent germinal centers compared with high mutation rates associated with T cell–dependent germinal centers. J Exp Med. 2002;195:383–9. · DOI
  51. Reynaud C, Garcia C, Hein WR, Weill J. Hypermutation generating the sheep immunoglobulin repertoire is an antigen-independent process. Cell. 1995;80:115–25. · DOI
  52. Sindhava VJ, Bondada S. Multiple regulatory mechanisms control B-1 B cell activation. Front Immunol. 2012;3:372. · DOI
  53. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med. 2011;208:67–80. · DOI
  54. Kantor AB, Herzenberg LA. Origin of murine B cell lineages. Annu Rev Immunol. 1993;11:501–38. · DOI
  55. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001;19:595–621. · DOI
  56. Kantor AB, Merrill CE, Herzenberg LA, Hillson JL. An unbiased analysis of V(H)-D-J(H) sequences from B-1a, B-1b, and conventional B cells. J Immunol. 1997;158:1175–86. · DOI
  57. Panda S, Zhang J, Tan NS, Ho B, Ding JL. Natural IgG antibodies provide innate protection against ficolin-opsonized bacteria. The. EMBO J. 2013;32:2905–19. · DOI
  58. Tornberg U, Holmberg DB-1a. B-1b and B-2 B cells display unique VHDJH repertoires formed at different stages of ontogeny and under different selection pressures. EMBO J. 1995;14:1680–9. · DOI
  59. Holodick NE, Vizconde T, Hopkins TJ, Rothstein TL. Age-related decline in natural IgM function: diversification and selection of the B-1a cell pool with age. J Immunol. 2016;196:4348–57. · DOI
  60. Yang Y, Wang C, Yang Q, Kantor AB, Chu H, Ghosn EEB, et al. Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires. eLife. 2015;4:e09083.
  61. Hooijkaas H, Benner R, Pleasants JR, Wostmann BS. Isotypes and specificities of immunoglobulins produced by germ-free mice fed chemically defined ultrafiltered “antigen-free” diet. Eur J Immunol. 1984;14:1127–30. · DOI
  62. MacKenzie CR, Hirama T, Deng S, Bundle DR, Narang SA, Young NM. Analysis by surface plasmon resonance of the influence of valence on the ligand binding affinity and kinetics of an anti-carbohydrate antibody. The. J Biol Chem. 1996;271:1527–33. · DOI
  63. Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin exp Immunol 1986;63:127–34.
  64. Hammarström L, Smith CIE. IgG2 deficiency in a healthy blood donor. Concomitant lack of IgG2, IgA and IgE immunoglobulins and specific anti-carbohydrate antibodies. Clin Exp Immunol. 1983;51:600–4.
  65. Yount WJ, Dorner MM, Kunkel HG, Kabat EA. Studies on human antibodies VI. Selective variations in subgroup composition and genetic markers. J Exp Med. 1968;127:633–46. · DOI
  66. Schneider C, Smith DF, Cummings RD, Boligan KF, Hamilton RG, Bochner BS, et al. The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci Transl Med. 2015;7:269ra1. · DOI
  67. von Gunten S, Smith DF, Cummings RD, Riedel S, Miescher S, Schaub A, et al. Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass. The. J allergy Clin Immunol. 2009;123:1268–76. · DOI
  68. Rollenske T, Szijarto V, Lukasiewicz J, Guachalla LM, Stojkovic K, Hartl K, et al. Cross-specificity of protective human antibodies against Klebsiella pneumoniae LPS O-antigen. Nat Immunol. 2018;19:617–24. · DOI
  69. Mantegazza AR, Magalhaes JG, Amigorena S, Marks MS. Presentation of phagocytosed antigens by MHC class I and II. Traffic. 2013;14:135–52. · DOI
  70. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443–73. · DOI
  71. Murphy KM, Weaver C. Die humorale Immunantwort. In: Murphy KM, Weaver C, editors. Janeway Immunologie, vol. Kapitel 10. Berlin, Heidelberg: Springer Spektrum; 2018, pp 517–80. · DOI
  72. Comstock LE, Kasper DL. Bacterial glycans: key mediators of diverse host immune responses. Cell. 2006;126:847–50. · DOI
  73. Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL. Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol. 2002;169:6149–53. · DOI
  74. Avci FY, Kasper DL. How bacterial carbohydrates influence the adaptive immune system. Annu Rev Immunol. 2010;28:107–30. · DOI
  75. Velez CD, Lewis CJ, Kasper DL, Cobb BA. Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation. Immunology. 2009;127:73–82. · DOI
  76. Tzianabos AO, Finberg RW, Wang Y, Chan M, Onderdonk AB, Jennings HJ, et al. T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem. 2000;275:6733–40. · DOI
  77. Tzianabos AO, Wang JY, Lee JC. Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides. Proc Natl Acad Sci USA. 2001;98:9365–70. · DOI
  78. Stein KE. Thymus-independent and thymus-depdent responses to polysaccharide antigens. J Infect Dis. 1992;165:S49–52. · DOI
  79. Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010;125(Suppl 2):S33–40. · DOI
  80. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type II. Annu Rev Immunol. 1995;13:655–92. · DOI
  81. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–3. · DOI
  82. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer J, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188:1185–90. · DOI
  83. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535:75–84. · DOI · Paper page
  84. Kim M, Kim CH. Regulation of humoral immunity by gut microbial products. Gut Microbes. 2017;8:392–9. · DOI · Paper page
  85. Teyton L. Role of lipid transfer proteins in loading CD1 Antigen Presenting Molecules. J Lipid Res. 2018;59:1367–73. · DOI
  86. Zajonc DM, Kronenberg M. CD1 mediated T cell recognition of glycolipids. Curr Opin Struct Biol. 2007;17:521–9. · DOI
  87. Young DC, Moody DB. T-cell recognition of glycolipids presented by CD1 proteins. Glycobiology. 2006;16:103R–12R. · DOI
  88. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol. 2004;22:817–90. · DOI
  89. Van de Perre P. Transfer of antibody via mother’s milk. Vaccine. 2003;21:3374–6. · DOI
  90. Schroeder HW, Zhang L, Philips JB. Slow, programmed maturation of the immunoglobulin HCDR3 repertoire during the third trimester of fetal life. Blood. 2001;98:2745–51. · DOI
  91. Zola H. The development of antibody responses in the infant. Immunol cell Biol. 1997;75:587–90. · DOI
  92. Nguyen QN, Himes JE, Martinez DR, Permar SR. The impact of the gut microbiota on humoral immunity to pathogens and vaccination in early infancy. PLoS Pathog. 2016;12:e1005997. · DOI
  93. Xia L, GildersleeveI JC. Anti-glycan IgM repertoires in newborn human cord blood. PLoS ONE. 2019;14:e0218575.
  94. New JS, King RG, Kearney JF. Manipulation of the glycan-specific natural antibody repertoire for immunotherapy. Immunol Rev. 2016;270:32–50. · DOI
  95. Wuttke NJ, Macardle PJ, Zola H. Blood group antibodies are made by CD5+ and by CD5- B cells. Immunol Cell Biol. 1997;75:478–83. · DOI
  96. Doenz U, Nydegger UE, Kueng A, Carrel T, Mohacsi P. Anti-galalpha1-3Gal IgM/IgG antibody levels in infants: do they have a clinical relevance in pediatric xenotransplantation?. J Heart Lung Transplant. 2000;19:1108–13. · DOI
  97. Springer GF, Williamson P, Brandes WC. Blood group activity of gram-negative bacteria. J Exp Med. 1961;113:1077–93. · DOI
  98. Springer GF, Horton RE. Blood group isoantibody stimulation in man by feeding blood group-active bacteria. J Clin Investig. 1969;48:1280–91. · DOI
  99. Kay LA. Cellular basis of immune response to antigens of the AB0 blood group system. Lancet. 1984;2:1369–71. · DOI
  100. Guo H, Yi W, Shao J, Lu Y, Zhang W, Song J, et al. Molecular analysis of the O-antigen gene cluster of Escherichia coli O86:B7 and characterization of the chain length determinant gene (wzz). Appl Environ Microbiol. 2005;71:7995–8001. · DOI
  101. Yilmaz B, Portugal S, Tran TM, Gozzelino R, Ramos S, Gomes J, et al. Gut microbiota elicits a protective immune response against malaria transmission. Cell. 2014;159:1277–89. · DOI
  102. Bello-Gil D, Audebert C, Olivera-Ardid S, Perez-Cruz M, Even G, Khasbiullina N, et al. The formation of glycan-specific natural antibodies repertoire in GalT-KO mice is determined by gut microbiota. Front Immunol. 2019;10:342. · DOI
  103. Kamada N, Chen GY, Inohara N, Nunez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14:685–90. · DOI · Paper page
  104. Macpherson AJ, Geuking MB, Slack E, Hapfelmeier S, Kathy D, McCoy KD, et al. The habitat, double life, citizenship, and forgetfulness of IgA. Immunological Rev. 2012;245:132–46. · DOI
  105. Bunker JJ, Flynn TM, Koval JC, Shaw DG, Meisel M, McDonald BD, et al. Innate and adaptive humoral responses coat distinct commensal bacteria with immunoglobulin A. Immunity. 2015;43:541–53. · DOI
  106. Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell. 2014;158:1000–10. · DOI · Paper page
  107. Allan E, Poxton IR, Barclay GR. Anti-bacteroides lipopolysaccharide IgG levels in healthy adults and sepsis patients. FEMS Immunol Med Microbiol. 1995;11:5–12. · DOI
  108. Manukyan GP, Ghazaryan KA, Ktsoyan ZA, Khachatryan ZA, Arakelova KA, Kelly D, et al. Elevated systemic antibodies towards commensal gut microbiota in autoinflammatory condition. PLoS ONE. 2008;3:e3172. · DOI
  109. Haas A, Zimmermann K, Graw F, Slack E, Rusert P, Ledergerber B, et al. Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut. 2011;60:1506–19. · DOI
  110. Cahenzli J, Koller Y, Wyss M, Geuking MB, McCoy KD. Intestinal microbial diversity during early-life colonization shapes long-term IgE levels. Cell Host Microbe. 2013;14:559–70. · DOI · Paper page
  111. Zeng MY, Cisalpino D, Varadarajan S, Hellman J, Warren HS, Cascalho M, et al. Gut microbiota-induced immunoglobulin G controls systemic infection by symbiotic bacteria and pathogens. Immunity. 2016;44:647–58. · DOI · Paper page
  112. Harmsen HJ, Pouwels SD, Funke A, Bos NA, Dijkstra G. Crohn’s disease patients have more IgG-binding fecal bacteria than controls. Clin Vaccin Immunol. 2012;19:515–21. · DOI
  113. Mohammed N, Tang L, Jahangiri A, de Villiers W, Eckhardt E. Elevated IgG levels against specific bacterial antigens in obese patients with diabetes and in mice with diet-induced obesity and glucose intolerance. Metab: Clin Exp. 2012;61:1211–4. · DOI
  114. Li X, Atkinson MA. The role for gut permeability in the pathogenesis of type 1 diabetes-a solid or leaky concept? Pediatr Diabetes. 2015;16:485–92. · DOI
  115. Michielan A, D’Inca R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015;2015:628157. · DOI · Paper page
  116. Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoel M, Lawson MAE, et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science. 2009;325:617–20. · DOI
  117. Zimmermann K, Haas A, Oxenius A. Systemic antibody responses to gut microbes in health and disease. Gut Microbes. 2012;3:42–7. · DOI
  118. Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol. 2013;18:479–97. · DOI
  119. Rescigno M, Urbano M, Valzasina B, Rotta G, Bonasio R, Granucci F, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2:361–7. · DOI
  120. Lelouard H, Fallet M, de Bovis B, Meresse S, Gorvel JP. Peyer’s patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores. Gastroenterology. 2012;142:592–601. e3. · DOI
  121. Clark MA, Hirst BH, Jepson MA. M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to Mouse Peyer’s patch M cells. Infect Immun. 1998;66:1237–43. · DOI
  122. Peterson DA, McNulty NP, Guruge JL, Gordon JI. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe. 2007;2:328–39. · DOI · Paper page
  123. Ravindran B, Satapathy AK, Das MK. Naturally-occurring anti-a-galactosyl antibodies in human Plasmodium falciparum infections - a possible role for autoantibodies in malaria. Immunol Lett. 1988;19:137–42. · DOI
  124. Yooseph S, Kirkness EF, Tran TM, Harkins DM, Jones MB, Torralba MG, et al. Stool microbiota composition is associated with the prospective risk of Plasmodium falciparum infection. BMC genomics. 2015;16:631–46. · DOI
  125. Soares MP, Yilmaz B. Microbiota control of malaria transmission. Trends Parasitol. 2016;32:120–30. · DOI
  126. Ngwa CJ, Pradel G. Coming soon: probiotics-based malaria vaccines. Trends Parasitol. 2015;31:2–4. · DOI
  127. Avila JL, Rojas M, Galili U. Immunogenic Gal-a1-3-Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J Immunol. 1989;142:2828–34. · DOI
  128. Avila JL, Rojas M, Towbin H. Serological activity against galactosyl-a(1-3)galactose in sera from patients with several kinetoplastida infections. J Clin Microbiol. 1988;26:126–32. · DOI
  129. Towbin H, Rosenfelder G, Wieslander J, Avila JL, Rojas M, Szarfman A, et al. Circulating antibodies to mouse laminin in Chagas disease, american cutaneous Leishmaniasis, and normal individual recognize terminal galactoysl(a1-3)-galactose epitopes. J Exp Med. 1987;166:419–32. · DOI
  130. Almeida IC, Milani SR, Gorin PA, Travassos LR. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies. J Immunol. 1991;146:2394–400. · DOI
  131. Gazzinelli RT. Natural anti-Gai antibodies prevent, rather than cause, autoimmunity in human Chagas’ disease. Res Immunol. 1991;142:164–7. · DOI
  132. Moura APV, Santos LCB, Brito CRN, Valencia E, Junqueira C, Filho AAP, et al. Virus-like particle display of the alpha-gal carbohydrate for vaccination against leishmania infection. ACS Cent Sci. 2017;3:1026–31. · DOI
  133. Schocker NS, Portillo S, Brito CR, Marques AF, Almeida IC, Michael K. Synthesis of Galalpha(1,3)Galbeta(1,4)GlcNAcalpha-, Galbeta(1,4)GlcNAcalpha- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease. Glycobiology. 2016;26:39–50.
  134. Hamadeh RM, Jarvis GA, Galili U, Mandrell RE, Zhou P, Griffiss JM. Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. J Clin Investig. 1992;89:1223–35. · DOI
  135. Van Nunen SA, O’Connor KS, Clarke LR, Boyle RX, Fernando SL. An association between tick bite reactions and red meat allergy in humans. Med J Aust. 2009;190:510–1. · DOI
  136. Commins SP, Satinover SM, Hosen J, Mozena J, Borish L, Lewis BD, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-α-1,3-galactose. J Allergy Clin Immunol. 2009;123:426–33. · DOI
  137. Commins SP, James HR, Kelly LA, Pochan SL, Workman LJ, Perzanowski MS, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J Allergy Clin Immunol. 2011;127:1286–93. · DOI · Paper page
  138. Araujo RN, Franco PF, Rodrigues H, Santos LCB, McKay CS, Sanhueza CA, et al. Amblyomma sculptum tick saliva: α-Gal identification, antibody response and possible association with red meat allergy in Brazil. Int J Parasitol. 2016;46:213–20. · DOI
  139. Hilger C, Fischer J, Wölbing F, Biedermann T. Role and mechanism of galactose-alpha-1,3-galactose in the elicitation of delayed anaphylactic reactions to red meat. Curr Allergy Asthma Rep. 2019;19:3. · DOI
  140. Apostolovic D, Tran TAT, Hamsten C, Starkhammar M, Cirkovic Velickovic T, van Hage M. Immunoproteomics of processed beef proteins reveal novel galactose-α-1,3-galactose-containing allergens. Allergy. 2014;69:1308–15. · DOI
  141. Chung CH, Beloo Mirakhur B, Emily Chan E, Le Q, Berlin J, Morse M, et al. Cetuximab-Induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008;358:1109–17. · DOI · Paper page
  142. Morisset M, Richard C, Astier C, Jacquenet S, Croizier A, Beaudouin E, et al. Anaphylaxis to pork kidney is related to IgE antibodies specific for galactose-alpha-1,3-galactose. Allergy. 2012;67:699–704. · DOI
  143. Steinke JW, Platts-Mills TAE, Commins SP. The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol. 2015;135:589–96. · DOI
  144. Saleh H, Embry S, Nauli A, Atyia S, Krishnaswamy G. Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution. clinical and molecular. Allergy. 2012;10:5.
  145. Damian RT. Molecular mimicry: antigen sharing by parasite and host and its consequences. Am Naturalist. 1964;98:129–49. · DOI
  146. Moran AP, Prendergast MM, Appelmelk BJ. Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. FEMS Immunol Med Microbiol. 1996;16:105–15. · DOI
  147. Gamian A, Beurret M, Michon F, Brisson JR, Jennings HJ. Structure of the L2 lipopolysaccharide core oligosaccharides Neisseria meningitidis. J Biol Chem. 1992;267:922–5. · DOI
  148. Michon F, Beurret M, Gamian A, Brisson JR, Jennings HJ. Structure of the L5 lipopolysaccharide core oligosaccharides of Neisseria meninigitidis. J Biol Chem. 1990;265:7243–7. · DOI
  149. Borrelli S, Roggen EL, Hendriksen D, Jonasson J, Ahmed HJ, Piot P, et al. Monoclonal antibodies against haemophilus lipopolysaccharides: clone DP8 Specific for Haemophilus ducreyi and Clone DH24 binding to lacto-N-neotetraose. Infect Immun. 1995;63:2665–73. · DOI
  150. Yamasaki R, Bacon BE, Nasholds W, Schneider H, Griffiss JM. Structural determination of oligosaccharides derived from lipooligosaccharide of Neisseria gonorrhoeae F62 by chemical, enzymatic, and two-dimensional NMR methods. Biochemistry. 1991;30:10566–75. · DOI
  151. Schweda EKH, Sundström AC, Eriksson LM, Jonasson JA, Lindberg AA. Structural studies of the cell envelope lipopolysaccharides from Heamophilus ducreyi strains ITM2665 and ITM4747. J Biol Chem. 1994;269:12040–8. · DOI
  152. Yamasaki R, Griffiss JM, Quinn KP, Mandrell RE. Neuraminic acid Is a2->3 linked in the lipooligosaccharide of Neisseria meningitidis serogroup B strain 6275. J Bacteriol. 1993;175:4565–8. · DOI
  153. Mandrell RE, Kim JJ, John CM, Gibson BW, Sugai JV, Apicella MA, et al. Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J Bacteriol. 1991;173:2823–32. · DOI
  154. de la Paz H, Cooket SJ, Heckels JE. Effect of sialylation of lipopolysaccharide of Neisseria gonorrhoeae on recognition and complement-mediated killing by monoclonal antibodies directed against different outer-membrane antigens. Microbiology. 1995;141:913–20. · DOI
  155. Hood DW, Makepeace K, Deadman ME, Rest RF, Thibault P, Martin A, et al. Sialic acid in the lipooligosaccharide of Haemophilus influenzae: strain distribution, influence on serum resistance and structural characterization. Mol Microbiol. 1999;33:679–92. · DOI
  156. Rutishauser U, Landmesser L. Polysialic acid in the plasticity of the developing and adult vertebrate nervous system. Trends Neurosci. 1996;19:422–7. · DOI
  157. Schrager HM, Rheinwald JG, Wessels MR. Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. J Clin Investig. 1996;98:1954–8. · DOI
  158. Garantziotis S, Savani RC. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 2019;78-79:1–10. · DOI
  159. Aspinall GO, Monteiro M. Lipopolysaccharides of Helicobacter pylori strains P466 and MO19: structures of the O antigen and core oligosaccharide regions. Biochemistry. 1996;35:2498–504. · DOI
  160. Brockhausen I. Crossroads between bacterial and mammalian glycosyltransferases. Front Immunol. 2014;5:492. · DOI
  161. Bouchet V, Hood DW, Li J, Brisson JR, Randle GA, Martin A, et al. Host-derived sialic acid is incorporated into Haemophilus influenzae lipopolysaccharide and is a major virulence factor in experimental otitis media. Proc Natl Acad Sci USA. 2003;100:8898–903. · DOI
  162. Hooper LV, Xu J, Falk PG, Midtvedt T, Gordon JI. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc Natl Acad Sci USA. 1999;96:9833–8. · DOI
  163. Coyne MJ, Reinap B, Lee MM, Comstock LE. Human symbionts use a host-like pathway for surface fucosylation. Science. 2005;307:1778–81. · DOI
  164. Ang CW, Jacobs BC, Laman JD. The Guillain-Barre syndrome: a true case of molecular mimicry. Trends Immunol. 2004;25:61–6. · DOI
  165. Olive J, Castillo C, Garcia Castro R, de Quadros CA. Epidemiologic study of Guillain-Barre syndrome in children <15 years of age in Latin America. J Infect Dis. 1997;175(Suppl 1):S160–4. · DOI
  166. Hahn AF. Guillain-Barré syndrome. Lancet. 1998;352:635–41. · DOI
  167. Yu RK, Usuki S, Ariga T. Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infect Immun. 2006;74:6517–27. · DOI
  168. Epps SV, Harvey RB, Hume ME, Phillips TD, Anderson RC, Nisbet DJ. Foodborne Campylobacter: infections, metabolism, pathogenesis and reservoirs. Int J Environ Res Public Health. 2013;10:6292–304. · DOI
  169. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al. Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology. 2001;56:758–65. · DOI
  170. Aspinall GO, Fujimoto S, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barre syndrome patients mimic human gangliosides in structure. Infect Immun. 1994;62:2122–5. · DOI
  171. Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barre Miller Fisher syndrome. J Infect Dis. 1997;176(Suppl 2):S150–3. · DOI
  172. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA. 2004;101:11404–9. · DOI
  173. Moran AP, Prendergast MM. Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J Autoimmun. 2001;16:241–56. · DOI
  174. Schwerer B. Antibodies against gangliosides: a link between preceding infection and immunopathogenesis of Guillain-Barré syndrome. Microbes Infect. 2002;4:373–84. · DOI
  175. Moran AP, Annuk H, Prendergast MM. Antibodies induced by ganglioside-mimicking Campylobacter jejuni lipooligosaccharides recognise epitopes at the nodes of Ranvier. J Neuroimmunol. 2005;165:179–85. · DOI
  176. Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 2011;122:155–70. · DOI
  177. Harris VK, Sadiq SA. Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagnosis Ther. 2014;18:605–17. · DOI
  178. Arnon R, Crisp E, Kelley R, Ellison GW, Myers LW, Tourtellotte WW. Anti-ganglioside antibodies in Multiple Sclerosis. J Neurol Sci. 1980;46:179–86. · DOI
  179. Endo T, Scott DD, Stewart SS, Kundu SK, Marcus DM. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol. 1984;132:1793–7. · DOI
  180. Schwarz M, Spector L, Gortler M, Weisshaus O, Glass-Marmor L, Karni A, et al. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci. 2006;244:59–68. · DOI
  181. Menge T, Lalive PH, von Budingen HC, Cree B, Hauser SL, Genain CP. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol. 2005;116:453–9. · DOI
  182. Grader-Beck T, Boin F, von Gunten S, Smith D, Rosen A, Bochner BS. Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease. Ann Rheum Dis. 2011;70:2218–24. · DOI
  183. Paul S, Boschetti G, Rinaudo-Gaujous M, Moreau A, Del Tedesco E, Bonneau J, et al. Association of anti-glycan antibodies and inflammatory bowel disease course. J Crohn’s Colitis. 2015;9:445–51. · DOI
  184. Kaul A, Hutfless S, Liu L, Bayless TM, Marohn MR, Li X. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:1872–84. · DOI
  185. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn’s disease behavior. Inflamm Bowel Dis. 2010;16:263–74. · DOI · Paper page
  186. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease. Gastroenterology. 2006;131:366–78. · DOI
  187. Kappler K, Lasanajak Y, Smith DF, Opitz L, Hennet T. Increased antibody response to fucosylated oligosaccharides and fucose-carrying Bacteroides species in Crohn’s disease. Front Microbiol. 2020;11:1553 · DOI
  188. Dai H, Li Z, Zhang Y, Lv P, Gao XM. Elevated levels of serum antibodies against Saccharomyces cerevisiae mannan in patients with systemic lupus erythematosus. Lupus. 2009;18:1087–90. · DOI
  189. Dotta F, Previti M, Neerman-Arbez M, Dionisi A, Cucinotta D, Lenti L, et al. The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granules and is not-cell specific. Endocrinology. 1998;139:316–9. · DOI
  190. Gillard BK, Thomas JW, Nell LJ, Marcus DM. Antibodies against ganglioside GT3 in the sera of patients with type I diabetes mellitus. J Immunol. 1989;142:3826–32. · DOI
  191. Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front Biosci. 2003;8:s533–43. · DOI
  192. Mende M, Bordoni V, Tsouka A, Loeffler FF, Delbianco M, Seeberger PH. Multivalent glycan arrays. Faraday Discuss. 2019;219:9–32. · DOI
  193. Schena M, Shalon D, Davis RW, Brownt PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467–70. · DOI · Paper page
  194. Fazio F, Bryan MC, Blixt O, Paulson JC, Wong CH. Synthesis of sugar arrays in microtiter plate. J Am Chem Soc. 2002;124:14397–402. · DOI
  195. Houseman BT, Mrksich M. Carbohydrate arrays for the evaluation of protein binding and enzymatic modification. Chem Biol. 2002;9:443–54. · DOI
  196. Wang D. Carbohydrate microarrays. Proteomics. 2003;3:2167–75. · DOI
  197. Geissner A, Seeberger PH. Glycan arrays: from basic biochemical research to bioanalytical and biomedical applications. Annu Rev Anal Chem. 2016;9:223–47. · DOI
  198. Song X, Heimburg-Molinaro J, Cummings RD, Smith DF. Chemistry of natural glycan microarrays. Curr Opin Chem Biol. 2014;18:70–7. · DOI
  199. Song X, Lasanajak Y, Xia B, Heimburg-Molinaro J, Rhea JM, Ju H, et al. Shotgun glycomics: a microarray strategy for functional glycomics. Nat methods. 2011;8:85–90. · DOI
  200. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA. 2004;101:17033–8. · DOI

200 of 218 shown

Cited by

Sorted by citations

See all 118

Metadata

Authors
Kappler, K., & Hennet, T.
Venue
Genes & Immunity
Publisher
Springer Science and Business Media LLC
Published
2020-08
Volume
21
Issue
4
Pages
224-239
ISSN
  • 1466-4879
  • 1476-5470
DOI
10.1038/s41435-020-0105-9
PMC
PMC7449879
Cited by
118
References
7
Language
en
Licence
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (314730_1728)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review